Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 2018 (2018), Article ID 1404813, 9 pages
https://doi.org/10.1155/2018/1404813
Review Article

Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli

Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada

Correspondence should be addressed to George G. Zhanel; ac.bm.scp@lenahzgg

Received 15 August 2017; Accepted 19 December 2017; Published 30 January 2018

Academic Editor: Cinzia Marianelli

Copyright © 2018 George G. Zhanel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. A. Lipsky, I. Byren, and C. T. Hoey, “Treatment of bacterial prostatitis,” Clinical Infectious Diseases, vol. 50, no. 12, pp. 1641–1652, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Zorman, M. Matičič, S. Jeverica, and T. Smrkolj, “Diagnosis and treatment of bacterial prostatitis,” Acta Dermatovenerologica Alpina Pannonica et Adriatica, vol. 24, no. 2, pp. 25–29, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. A. J. Denisuik, P. R. S. Lagacé-Wiens, J. D. Pitout et al., “Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007–11,” Journal of Antimicrobial Chemotherapy, vol. 68, no. 1, pp. i57–i65, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. J. A. Karlowsky, H. J. Adam, M. R. Baxter et al., “The in vitro activity of fosfomycin against antimicrobial-resistant Escherichia coli isolated from outpatient urine samples: CANWARD surveillance study 2007–2015,” in Proceedings of the CACMID-AMMI Conference, Toronto, ON, Canada, April 2017.
  5. J. A. Karlowsky, P. R. S. Lagacé-Wiens, P. J. Simner et al., “Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 7, pp. 3169–3175, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Karlowsky, A. J. Denisuik, P. R. S. Lagacé-Wiens et al., “In vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 2, pp. 1252–1256, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Los-Arcos, C. Pigrau, D. Rodríguez-Pardo et al., “Long-term fosfomycin-tromethamine oral therapy for difficult-to-treat chronic bacterial prostatitis,” Antimicrobial Agents and Chemotherapy, vol. 60, no. 3, pp. 1854–1858, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. G. G. Zhanel, A. J. Walkty, and J. A. Karlowsky, “Fosfomycin: a first-line oral therapy for acute uncomplicated cystitis,” Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 2016, Article ID 2082693, 10 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. B. J. Gardiner, A. A. Mahony, A. G. Ellis et al., “Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis?” Clinical Infectious Diseases, vol. 58, no. 4, pp. 101–105, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. A. S. Michalopoulos, I. G. Livaditis, and V. Gougoutas, “The revival of fosfomycin,” International Journal of Infectious Diseases, vol. 15, no. 11, pp. 732–739, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. M. E. Falagas and P. I. Rafailidis, “Fosfomycin: the current status of the drug,” Clinical Infectious Diseases, vol. 61, no. 7, pp. 1144–1146, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. T. J. Coker and D. M. Dierfeldt, “Acute bacterial prostatitis: diagnosis and management,” American Family Physician, vol. 93, no. 2, pp. 144–120, 2016. View at Google Scholar
  13. B. C. Gill and D. A. Shoskes, “Bacterial prostatitis,” Current Opinion in Infectious Diseases, vol. 29, no. 1, pp. 86–91, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. V. J. Sharp, E. B. Takacs, and C. R. Powell, “Prostatitis: diagnosis and treatment,” American Family Physician, vol. 82, no. 4, pp. 397–406, 2015. View at Google Scholar
  15. F. M. E. Wagenlehner, F. Kees, W. Weidner, C. Wagenlehner, and K. G. Naber, “Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers,” International Journal of Antimicrobial Agents, vol. 31, no. 1, pp. 21–26, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Perletti, E. Marras, F. M. Wagenlehner, and V. Magri, “Antimicrobial therapy for chronic bacterial prostatitis,” Cochrane Database of Systematic Reviews, no. 8, p. CD009071, 2013. View at Publisher · View at Google Scholar
  17. M. Nicolas-Chanoine, X. Bertrand, and J. Madec, “Escherichia coli ST131, an intriguing clonal group,” Clinical Microbiology Reviews, vol. 27, no. 3, pp. 543–574, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Kanamori, C. M. Parobek, J. J. Juliano et al., “Genomic analysis of multidrug-resistant Escherichia coli from North Carolina community hospitals: ongoing circulation of CTX-M-producing ST131–H30Rx and ST131-H30R1 strains,” Antimicrobial Agents and Chemotherapy, vol. 61, no. 8, pp. e00912–e00917, 2017. View at Publisher · View at Google Scholar
  19. J. R. Johnson, B. Johnston, M. A. Kuskowski, E. V. Sokurenko, and V. Tchesnokova, “Intensity and mechanisms of fluoroquinolone resistance within the H30 and H30Rx subclones of Escherichia coli sequence type 131 compared with other fluoroquinolone-resistant E. coli,” Antimicrobial Agents and Chemotherapy, vol. 59, no. 8, pp. 4471–4480, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. M. L. Mezzatesta, G. La Rosa, G. Maugeri et al., “In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens,” International Journal of Antimicrobial Agents, vol. 49, no. 6, pp. 763–766, 2017. View at Publisher · View at Google Scholar · View at Scopus
  21. J. N. Krieger and P. Thumbikat, “Bacterial prostatitis: bacterial virulence, clinical outcomes, and new directions,” Microbiology Spectrum, vol. 4, no. 1, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. B. A. Cunha, A. Gran, and M. Raza, “Persistent extended-spectrum β-lactamase-positive Escherichia coli chronic prostatitis successfully treated with a combination of fosfomycin and doxycycline,” International Journal of Antimicrobial Agents, vol. 45, no. 4, pp. 427–429, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. N. J. Rhodes, B. J. Gardiner, M. N. Neely et al., “Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis,” Journal of Antimicrobial Chemotherapy, vol. 70, no. 7, pp. 2068–2073, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. M. L. Grayson, N. Macesic, J. Trevillyan et al., “Fosfomycin for treatment of prostatitis: new tricks for old dogs,” Clinical Infectious Diseases, vol. 61, no. 7, pp. 1141–1143, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. I. Karaiskos, N. Moussas, V. Sakka et al., “Oral fosfomycin for the treatment of chronic prostatitis,” in Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2015), San Diego, CA, USA, September 2015.